To send content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about sending content to .
To send content items to your Kindle, first ensure email@example.com
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about sending to your Kindle.
Note you can select to send to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter talks about Hashimoto encephalopathy and the treatment-responsive encephalopathies associated with antibodies to neuronal antigens. Epilepsy has also been associated with the inflammatory bowel diseases (ulcerative colitis, Crohn disease, and celiac disease), although this association is more contentious. The chapter discusses the clinical features and treatment options for limbic encephalitis (LE) and the association of LE with epilepsy. Hu/ANNA-1, Ma-2, collapsin-response-mediator protein, amphiphysin and glutamic acid decarboxylase are intracellular antigens associated with LE. Voltage-gated potassium channels, N-methyl-D-aspartate receptor are extracellular antigens associated with LE. Accepted medical treatments for surface-antigen-related LE are high-dose steroids, plasma exchange, and/or intravenous immunoglobulin (IVIG), which are sometimes given in combination. The index disease for autoimmune thyroiditis group of immune-mediated epilepsy syndromes is the entity known as Hashimoto encephalopathy or steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT). The chapter also discusses the management of inflammatory bowel disease (IBD) and SREAT.